Treatment of opportunistic mycoses: how long is long enough?

被引:29
作者
Singh, N [1 ]
机构
[1] Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Pittsburgh, PA USA
关键词
D O I
10.1016/S1473-3099(03)00802-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
For most opportunistic mycoses no optimum duration of antifungal therapy has been defined. Although a long course of therapy is prudent, especially for mycelial fungal infections, excessively and unnecessarily extended courses of treatment incur a risk of toxicity and the expense of the therapeutic regimen. On the basis of existing reports on the pathogenesis and the effect of duration of therapy and other variables on outcome and response rate in fungal infections, this review proposes guidelines that may facilitate a rational approach to decision-making about the duration of antifungal therapy.
引用
收藏
页码:703 / 708
页数:6
相关论文
共 40 条
[1]   Predictors of adverse outcome in cancer patients with candidemia [J].
Anaissie, EJ ;
Rex, JH ;
Uzun, Ö ;
Vartivarian, S .
AMERICAN JOURNAL OF MEDICINE, 1998, 104 (03) :238-245
[2]  
BECKSAGUE CM, 1993, J INFECT DIS, V167, P1247, DOI 10.1093/infdis/167.5.1247
[3]   A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients [J].
Bowden, R ;
Chandrasekar, P ;
White, MH ;
Li, X ;
Pietrelli, L ;
Gurwith, M ;
van Burik, JA ;
Laverdiere, M ;
Safrin, S ;
Wingard, JR .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (04) :359-366
[4]   Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia [J].
Caillot, D ;
Couaillier, JF ;
Bernard, A ;
Casasnovas, O ;
Denning, DW ;
Mannone, L ;
Lopez, J ;
Couillault, G ;
Piard, F ;
Vagner, O ;
Guy, H .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) :253-259
[5]   Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS [J].
Caillot, D ;
Bassaris, H ;
McGeer, A ;
Arthur, C ;
Prentice, HG ;
Seifert, W ;
De Beule, K .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) :E83-E90
[6]   Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis [J].
Denning, DW ;
Ribaud, P ;
Milpied, N ;
Caillot, D ;
Herbrecht, R ;
Thiel, E ;
Haas, A ;
Ruhnke, M ;
Lode, H .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :563-571
[7]   Therapeutic outcome in invasive aspergillosis [J].
Denning, DW .
CLINICAL INFECTIOUS DISEASES, 1996, 23 (03) :608-615
[8]   International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections [J].
Edwards, JE ;
Bodey, GP ;
Bowden, RA ;
Buchner, T ;
dePauw, BE ;
Filler, SG ;
Ghannoum, MA ;
Glauser, M ;
Herbrecht, R ;
Kauffman, CA ;
Kohno, S ;
Martino, P ;
Meunier, F ;
Mori, T ;
Pfaller, MA ;
Rex, JH ;
Rogers, TR ;
Rubin, RH ;
Solomkin, J ;
Viscoli, C ;
Walsh, TJ ;
White, M .
CLINICAL INFECTIOUS DISEASES, 1997, 25 (01) :43-59
[9]   A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B [J].
Fichtenbaum, CJ ;
German, M ;
Dunagan, WC ;
Fraser, VJ ;
Medoff, G ;
Diego, J ;
Powderly, WG .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (06) :1551-1556
[10]   Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis [J].
Graybill, JR ;
Sobel, J ;
Saag, M ;
van der Horst, C ;
Powderly, W ;
Cloud, G ;
Riser, L ;
Hamill, R ;
Dismukes, W .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (01) :47-54